Veltuzumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011[update], it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD20 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6458H9918N1706O2026S46 |
| Molar mass | 145349.06 g·mol−1 |
  (what is this?) (verify) | |
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]
In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]
